FDA 483 - BrightGene BioMedical Technology Co., Ltd. - August 10, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of BrightGene Bio-Medical Technology Co., Ltd. in Suzhou, China, revealed significant deficiencies within its quality control unit. The firm failed to adhere to established procedures, including a lack of raw data for vendor calibrations, incomplete data review forms for released batches, and inadequate investigations into system suitability failures and audit trail issues. These observations indicate a systemic breakdown in maintaining proper quality oversight and data integrity.
ID · bdd38797-112c-4ac5-88ee-c5572771eeb5